AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps7074
Abstract: TPS7074Background: Acute myeloid leukemia (AML) is a hematologic malignancy with limited treatment options for patients who are ineligible for intensive chemotherapy, corresponding to a median over... read more here.
Keywords: agile phase; myeloid leukemia; phase multicenter; acute myeloid ... See more keywords